18. February 2020
Fabry disease, an X-linked inherited lysosomal storage disorder, can be overlooked in heterozygous females due to random X-inactivation. In...Read more
6. June 2019
We are happy to inform you that we have introduced a new diagnostic assay for the analysis of lysosomal...Read more
14. March 2018
LEA2 MPS Panel Our first LEA2 (Lysosomal Enzyme Activity) assay has now been started and with it several mucopolysaccharidoses...Read more
7. March 2018
The parallel measurement of lyso-GL-3 (lyso-Gb3) for Fabry disease is of high importance particularly for potential female Fabry patients,...Read more
29. November 2011
Background: The interest in neonatal screening for lysosomal storage disorders has increased substantially because of newly developed enzyme replacement...Read more
Started in 2013, ARCHIMEDlife is an independent highly-innovative company dedicated in providing and developing diagnostic services from Inborn Errors of Metabolism to Oncological Diseases. Our commitment is to provide better and faster high-quality laboratory tests for you and your family.
Our diagnostic laboratory is offering services from Clinical Mass Spectrometry to Next-Generation Sequencing. We have international collaborations with physicians, clinical researchers and industry specialized in personalized health care.
We are dedicated to the development of novel laboratory tests to make actionable health information accessible at the time it matters.